-
EP3166940
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3166940
| EP3166940 - QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 22.03.2019 Database last updated on 14.11.2024 | |
| Former | Request for examination was made Status updated on 18.04.2017 | ||
| Former | The international publication has been made Status updated on 20.01.2017 | Most recent event Tooltip | 22.03.2019 | Application deemed to be withdrawn | published on 24.04.2019 [2019/17] | Applicant(s) | For all designated states Alpharmagen, LLC 400 S El Camino Real No. 1200 San Mateo, CA 94402 / US | [2017/20] | Inventor(s) | 01 /
BILCER, Geoffrey M. 27635 Virginia Cove Shorewood, MN 55331 / US | 02 /
NG, Raymond 189 Valdivia Circle San Ramon, CA 94583 / US | [2017/20] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2017/20] | Wytenburg, Wilhelmus Johannes, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 15819578.4 | 08.07.2015 | [2017/20] | WO2015US39560 | Priority number, date | US201462023580P | 11.07.2014 Original published format: US 201462023580 P | [2017/20] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016007630 | Date: | 14.01.2016 | Language: | EN | [2016/02] | Type: | A1 Application with search report | No.: | EP3166940 | Date: | 17.05.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.01.2016 takes the place of the publication of the European patent application. | [2017/20] | Search report(s) | International search report - published on: | AU | 14.01.2016 | (Supplementary) European search report - dispatched on: | EP | 28.03.2018 | Classification | IPC: | C07D453/02, A61K31/439, C07D471/08, C07D209/04, A61P25/28 | [2017/20] | CPC: |
C07D453/02 (EP,US);
A61K31/439 (EP,US);
A61K45/06 (EP,US);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/14 (EP);
A61P25/16 (EP);
A61P25/18 (EP);
A61P25/22 (EP);
A61P25/24 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/20] | Title | German: | CHINUCLIDINVERBINDUNGEN ZUR MODULIERUNG DER AKTIVITÄT DES ALPHA7-NIKOTINISCHEN ACETYLCHOLINREZEPTORS | [2017/20] | English: | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | [2017/20] | French: | COMPOSÉS DE QUINUCLIDINE POUR MODULER L'ACTIVITÉ DU RÉCEPTEUR NICOTINIQUE ALPHA7 DE L'ACÉTYLCHOLINE | [2017/20] | Entry into regional phase | 20.01.2017 | National basic fee paid | 20.01.2017 | Search fee paid | 20.01.2017 | Designation fee(s) paid | 20.01.2017 | Examination fee paid | Examination procedure | 20.01.2017 | Examination requested [2017/20] | 20.01.2017 | Date on which the examining division has become responsible | 29.08.2017 | Loss of particular rights, legal effect: Claims | 04.10.2017 | Despatch of communication of loss of particular rights: Claims {1} | 24.10.2018 | Application deemed to be withdrawn, date of legal effect [2019/17] | 05.12.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/17] | Fees paid | Renewal fee | 12.07.2017 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.07.2018 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [ ] - No further relevant documents disclosed | International search | [X]US2009088418 (PFISTER JURG R [US], et al) [X] 1-39 * see page 2 para [0017], page 7 para [0079] and claim 1; page 16 para [0173] - [0178] and page 20-26 examples 1-33; page 17 para [0183]; abstract; page 16 para [0182]; page 19 column 2 lines 4-7; page 19 para [0207]; page 4 para [0046]; pages 19-20 para [0210] - [0219]. *; | [A]WO2008118742 (ABBOTT LAB [US], et al) [A] 1-39 * see page 57 example 40; page 4-5 para [0016] - [0017]. *; | [A]DE3810552 (SANDOZ AG [DE]) [A] 1-39 * see page 17 compound 9 in table. *; | [A]EP0309423 (ANGELI INST SPA [IT]) [A] 1-39 * see page 16 line 10 compound 21; page 2 lines 5-8. *; | [A] - TURC ONI, M. et al., "Synthesis of a new class of 2,3-dihydro-2-oxo-1 H- benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists", Journal of Medicinal Chemistry, (19900000), vol. 33, no. 8, doi:doi:10.1021/jm00170a009, pages 2101 - 2108, XP002947713 [A] 1-39 * . see page 2103 compound 11 c; title. * DOI: http://dx.doi.org/10.1021/jm00170a009 |